Unavo idably, much medical practice is based on impression and experience rather than evidence. When evidence is available, we are usually more comfortable with our practice decisions. However, we should also remember that utilization of evidence -based data includes interpretation and j udgments. It seems healthy to review the assu mptio ns underlying such j udg ments periodica lly. The widespread decision to abandon stapes mobilization in favor of stapedectomy warran ts reco nsidera tion.
Most oto logists stopped perform ing stapes mobi lization years ago because of its high failure rate. I have continued to perform stapes mobi lization electively (following a comprehensive consent discussion wit h my patients) throughout my practice, having learned the procedure from my father, Joseph Sataloff, who performed approximately 10,000 stapes operations, many of them mobilizations. This decision is not because ofa disagreement with any ofthe data that were utilized by the oto logists who advocated abandoning stapes mobilization in favor of stape dectomy. Rather, it is based on a different stra tification of priorities, which resulted in a j udgment in favor of stapes mobil ization, base d on the same data .
In 1979, Brook ler published an article reviewing 120,132 stapedectomy cases.' He identified sensorineural hearing loss reported in 0.97% (approximately I%) of cases .
It was not possible to separate "dead" ears from less severe sensorineural hearing loss in all of these cases. Most active oto logists agree that the incidence is at least I to 2% commonly, and probably higher in less expe rienced hands. I have reviewed many ofthe published articles on stapes mobilization, totaling 10,811 cases.':" These articles revea led a 0.036% incidence of sensori neural hearing loss and a 0.064% incidence of "dead" ears . Thi s results in a total sensorineural hearing loss incide nce of approximately 0.1% amo ng stapes mobilization patie nts, a tenfo ld decrease in comparison with stapedectomy.
The reported long-term success rate of stapes mobi lizations gleaned from these articles was about 55% . This number has remai ned acce pted for deca des, perhaps because no one has tried to improve it. However, if we were to initiate research to adva nce the techniqu es and outcomes ofstapes mobili zation surgery (to be rev iewed at grea ter length in a future issue of ENT JOURNAL), it is conceiva ble that better outcomes might prove possi ble . Nevertheless, this edito rial assu mes a "failure" rate of abo ut 50% .
There is something intrinsically unappealing about a procedure with a failure rate that approaches 50%, but we still must ask whet her it is worth paying the price necessary to achieve a "success" rate closer to 98% by performing stapedectomy instead of stapes mobilization. At the begin ning of my career, I decided that it was not, and that j udgme nt has not changed. 
CONTRAINDICATIONS
Hypersensitivityto any of the ingredients in this preparation contraindicates the use of RHINOCORT AQUA Nasal Spray.
WARNINGS
The replacement of asystemiccorticosteroid with atop ical corticosteroid can be accompanied by signs ofadrenal insufficiency, and inaddition some patients mayexperience symptoms ofcorticosteroidwithdrawal, eg, jointand/or muscular pain,lassitude, and depression.Patients previ ouslytreated for prolonged periods with systemic corticosteroidsand transferred to topical corticosteroidsshouid be carefully monitored foracute adrenal insufficiency in response to stress. In those patients who have asthma or other clinical condit ions requiring long-term systemic corticosteroid treatment, too rapid adecrease in syst emic corticosteroids maycause asevere exacerbation oftheir symptoms. Patients whoareon drugs which suppress the immunesystemare more susceptibleto infectionsthan healthy indivi duals. Chicken pox and measles, for example, can have a more serious or even fatal course in nonimmune children oradultson immunosuppressant doses ofcorticosteroids. Insuch children oradults whohave not had these diseases, parti cular care should be taken toavoid exposure. Howthe dose, route, anddurationof corticosteroid administration aff ects therisk ofdeveloping a disseminated infection is not known. Thecontribution otthe underlyi ng disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chicken pox, prophylaxis withvaricellazoster immuneglobulin (VZIG) may be indicated . If exposed to measles, prophylaxiswi th pooled intramuscularimmunoglobulin(IG) may be indicated. (Seethe respectivepackage inserts forcomplete VZIG and IG prescribing inform ation). It chickenpox develops, treatment with antiviralagents may be consid er ed. in Sprague-Dawl ey rats, budesonidecaused astatistically significant increase inthe incidence otgliomas inthe male rats receiving an oraldoseof 50mcglkg(approximately twice the maximum recommended daily int ranasal dose in adultsandchildren onamcg/m 2 basis). No tumorigenici tywasseen inmaleand female ratsatrespective oral doses up to25and50mcglkg(approximatelyequal toand twofimes fhemaximum reco mmended dailyint ranasal dose inadults and children on amcg/m 2 basis, respectivel y). Intwoadditional two-year studies inmale FischerandSprague-Dawley rats, budesonidecaused nogliomas at an oral dose of50 mcg/kg (approxi matelytwi cethe maximum recommended daily intranasal dose inadults and children on a mcg/m 2 basis). However, in male Sprague-Dawley rats, budesonide cau sed astat isti callysignificant increase intheincidence ofhepat ocellular tumorsatan oraldoseof50 mcglkg(approximately twice the maximum recomm ended daily intranasal dose in adults and children on a mcg/m 2 basis). The concu rrent referencecorticosteroids (prednisoloneandfriamcinolone acet onide)inthesetwo studies showed similar findings. In a 91 -1 'leek study in mi ce, budesonide caused notreatment-related ca rcinogenicity at oral doses upto 200 mcglkg (approximately 3 tim es the maximum recom mended daily intranasal dose in adulfs and children on a mcg/m 2 basis). Budesonidewas not mutagenic orclastogenic in si x diff er ent test systems: Ames Salmonella/microsomeplatetest, mouse micronucleustest, mouse lymphomatest, chromosome aberrationtest inhumanlymphocytes, sex-linked recessivelethal festinDrosophil a melanogaster, and DNArepair analysis inrathematocyte culture. Inrats, budesonide caused adecrease in prenatal viabilityand vi ability ofthepups at birth and during lactation, along witha decrease inmaternalbody-weight gain,atsubcutaneousdosesof 20 mcglkgand above (lessthan the maximum recommended daily intranasal dose in adults on a mcg/m 2 basi s). No such effects werenoted at5 mcglkg(less than the maximum recommended dail y intranasal dose in adults on a mcg/m 2 basis). Pregnancy: Teratogenic Effects: Pregnancy Category B: The impact of budesonide on human pregnancy outcomes has been evaluated through assessmentsof birt h registries linked with maternal usage of inhaled budesonide (ie, PULMICORT TURBUHALER) and intranasally adminis tered budesonide (ie, RH INOCORT AQUANasalSpray). Theresultsfrom population-based prospective cohort epidemiological studies reviewingdata from threeSwedish registriescovering approximately 99% of the pregnancies from 1995-2001 (i.e., SwedishMedical Birth Registry; Registry of Congenital Malformations; ChildCardiology Registry) indicateno increased riskforoverallcongen ital malformations from the use ofinhaled or intranasal budesonide during early pregnancy. Congenital malformations were studied in 2,01 4 infants born to mothers reporting the use ofinhaled budesonide forasthma inearly pregnancy (usually 10-1 2weeks aft erthe last menstrual period), the period when mostmajor organ malformations occur.' The rate of overallcon genital malformations was similar compared tothe general population rate (3. B%vs. 3.5%,respectively).The number ofinfants born with orofacialclefts an dcard iac defects was similartotheexpected number in the general population (4children vs. 3.3and 18 children vs. 17-18, respectively). In afollow-on study bringing the total numberof infants to 2,534, the rate ofoverall congenital malformations among infants whosemotherswereexposed to inhaled bu desonide during earlypregnancywas not different fromthe rateforall newborn babies dur ingthesame period (3.6%). 2 A thi rd study from the Swedish Medical Birth Registry of 2,968 pregnancies exposed to inhaled budesonide, the majority ofwhichwerefirsttrimester exposures, reportedgestationalage, birth weight, birth length, stillbirths, and multiplebirths similar forexposed infants comparedtononexposed infants. 3 Congenital malformations werestud ied in 2,113infants born to mothers repo rting the use of int ranasal budesonide in early pregnancy. The rate of overall congenital malformations was similar compared to the general population rate (4.5% vs. 3.5%, respectively). The adjusted odd sratio (OR) was 1.06 (95%CI 0.86 -1.31). The number ofinfantsborn with orotacial clefts was simil ar to the expected number in the general population (3children vs. 3, respectively). The number of infants born with cardiac defects exceeded that expected in the general population (28 children vs. 17.8 respectively). Thesystemic exposure from intranasal budesonide is 6-fold less than from inhaled budesonide andan association of cardiac defects was not seen with higher exposuresof budesonide. As withother corticosteroids, budesonide was teratogeni c and embryocidal in rabbits and rats. Budesonide prod uced fetal loss, decreased pupwei ghts, andskeletal abnormalitiesat sub cutaneousdoses of25mcg/kginrabbitsand 500 mcg/kg inrats (approximately 2and 16times themaximum recommendeddaily intranasal dose in adults onamcg/m 2 basis). In another studyinrats, noteratogenic orembryocidal eff ects wereseen atinhalation doses upto250 mcg/kg (approximately 8times the maximum recommended daily intranasal dose in adults ona mcg/m 2 basis). Experience with oral corticosteroidssince their introduction inpharmacologic, asopposed tophysiologic doses suggests that rode ntsare morepronetoteratogenic effects from corticosteroids than humans. In addition, because there is an increase in corticosteroid production during pregnancy, mostwomen will require alower exogenous corticosteroid dose and many will not need corticosteroid treatment during pregnancy. Despi tethe animal find ings, it wouldappear that the possibilityoffetal harmis remote if thedrugisused during pregnancy. Neverthe less, because the studies inhumans cannot ruleou t the possibility ofharm, RH INOCORTAQUA should be used duringpregnan cyonly if clearly needed. Nonteratogenic Eff ects: Hypoadrenalism may occur in infants born of mothers receiving corticosteroids during pregnancy. Such infants should be carefully observed. Nursing Mot hers: It is not known whether budesonide is excreted in human milk. Because other corticosteroids are excreted in human milk, caution should be exercised when RHINOCORT AQUA Nasal Spray isadministered tonursingwomen. Pediatric Use: Safetyand effectiveness inpediat ric patientsbelow6 years of age have not been established. Controlled cl inical studies have shown that intranasal corticosteroids may ca use areductioningrowt hvelocityinpediatricpatients. This effect has been observed inthe absence oflaboratory evidence ofhypothalamic-pituitary-ad renal (HPA)-axis suppression, suggesting that growth velocity isamore sensitive indicatorofsystemiccorticosteroid exposure in pediatricpatients than some commonly usedtests ofHPA-axis function. The long-term effects of this reduction in growth velocity associated with intranasal corticosteroids, includingthe impact on final adult height, are unknown.Thepotenti alfor"catchup" growt hfollowing discontinuation of treatment wi th intranasal corticosteroids has not been adequately studied. The growth of pediatric patients receivi ngintr anasalcorticosteroi ds, includi ngRHINOCORTAQUA Nasal Spray, shouldbe monitored routinely(eg,via stadiometry). The potential growth effects of prolonged treatment should be weighed against clinical benefits obtained andthe avai labilityofsafe and effective noncorticosteroid treatment alternatives. To minimize the systemic effectsofintranasalcorticosteroids, includi ng RHINOCORT AQ UA Nasal Spray, each patientshouldbe titrated tothe lowest dose that effectively controls his/her symptoms. A one-year placebo-controlled clinical growt h stUdy was conducted in229 pediatricpatients (ages4through8yearsofage) toassess the effect ofRH INOCORT AQUA (si ngledaily dose of64 mcg, therecommended starting dose for children ages 6yearsand above) ong rov~h velocity. From apopulation of141 patients receiving RHINOCORT AQUA Nasal Spray and 67receiving placebo, the point estimate for growth ve locitywi thRHINOCORTAQUA Nasal Spray was 0.25 crnyearlower than that noted with placebo (95% confidence interval ranging from 0.59cm/year lowerthan pl aceboto0.08 em/year higher thanplacebo). Thepotential for RHINOCORT AQ UA tocause growth suppression insusceptible patients orwhengivenatdoses above64mcg dailycannot be ruled out.The recommendeddosage range inpatients6to 11 years of age is 64to128mcg per day (see DOSAG EANDADMINISTRATION). GeriatricUse: Ofthe 2,461patients incli nical studies ofRHINOCORTAQUA Nasal Spray, 5% were 60 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, except foran adverse event reporting frequency of epistaxis which increased withage. Further , other reported clinical experience has not identified any other differences inresponses between elderly andyounger patients, butgreater sensiti vity of some older individuals cannot be ruledout.
ADVERSE REACTIONS
Th e inci denceof common adverse reactions is based upon two U.S. andfive non-U.S. cont rolled clinical trials in 1,526patients1110females and 239 males lessthan 18yearsofage,and 635 females and 542 males18yearsofage and older] treated withRHINOCORTAQUA Nasal Spray at doses upto400 mcg once daily for 3-6 weeks.Thetable belowdescribes adverse events occurring atan incidence of2%orgreater and morecommon among RHINOCORT AQ UA Nasal Spray-treated patients than in placebo-treated patients incontro lled clinical trials. Th eoverall incidence ofadverse eventswassimi lar between RHINOCORTAQUA and placebo. 
